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Background: The aim of our study was to explore and evaluate the relationship between insulin resistance and
progression of coronary atherosclerotic plaques. With the great burden coronary heart disease is imposing on
individuals, healthcare professionals have already embarked on determining its potential modifiable risk factors in
the light of preventive medicine. Insulin resistance has been generally recognized as a novel risk factor based on
epidemiological studies; however, few researches have focused on its effect on coronary atherosclerotic plaque
progression.
Methods: From June 7, 2007 to December 30, 2011, 366 patients received their index coronary angiogram and
were subsequently found to have coronary atherosclerotic plaques or normal angiograms were consecutively
enrolled in the study by the department of cardiology at the Ruijin Hospital, which is affiliated to the Shanghai
Jiaotong University School of Medicine. All patients had follow-up angiograms after the 1-year period for evaluating
the progression of the coronary lesions. The modified Gensini score was adopted for assessing coronary lesions
while the HOMA-IR method was utilized for determining the state of their insulin resistance. Baseline characteristics
and laboratory test results were described and the binomial regression analysis was conducted to investigate the
relationship between insulin resistance and coronary atherosclerotic plaque progression.
Results: Index and follow-up Gensini scores were similar between the higher insulin lower insulin resistant groups
(9.09 ± 14.33 vs 9.44 ± 12.88, p= 0.813 and 17.21 ± 18.46 vs 14.09 ± 14.18, p =0.358). However the Gensini score
assessing coronary lesion progression between both visits was significantly elevated in the higher insulin resistant
group (8.13 ± 11.83 versus 4.65 ± 7.58, p= 0.019). Multivariate logistic binomial regression analysis revealed that
insulin resistance (HOMA-IR> 3.4583) was an independent predictor for coronary arterial plaque progression
(OR = 4.969, p= 0.011). We also divided all the participants into a diabetic (n = 136) and a non-diabetic group
(n = 230), and HOMA-IR remained an independent predictor for atherosclerosis plaque progression.
Conclusions: Insulin resistance is an independent predictor of atherosclerosis plaque progression in patients with
coronary heart disease in both the diabetic and non-diabetic population.
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Although drug-eluting stents prevail in treating coronary
heart disease (CHD), several concerns have already
begun to rise publicly, including those regarding medical
complications social burdens [1]. More cost-effective
preventive treatments are called for; therefore, various
studies have been conducted to identify the risk factors
for CHD, which are classified into classical versus novel
categories [2]. The former consists of aging, female sex,
genetic factors, obesity, smoking, dyslipidemia, hyperten-
sion and diabetes mellitus while the latter includes sev-
eral inflammatory markers such as hsCRP, IL-6, TNF-α,
PAI-1, MCP-1 and adhesion factors such as ICAM-1 and
VCAM-1 [2]. Some studies also divert their targets on
the specific group of patients such as patients with
hypertension, diabetes, metabolic syndrome or even SLE
to personalize the existing grading systems of risk factors
including the classic Framingham, Reynolds, SCORE and
ASSIGN [2]. Insulin resistance, frequently appears in
various clinical settings such as hypertension, diabetes
and metabolic syndrome and is believed to be respon-
sible for connecting endocrinological disorders with their
potential adverse cardiovascular complications based on
its reciprocal relationship with endothelial dysfunction
indicated by cellular, physiological, clinical, and epi-
demiological studies [3–5]. However, few studies have ac-
tually examined its relationship with the progression of
coronary atherosclerotic plaques. The aim of our study
was to explore the effect of insulin resistance on the pro-
gression atherosclerotic plaques in patients with CHD.
Methods
Since June 7th, 2007 to Dec 30th, 2011, subjects were
identified and screened from patients seeking a planned
percutaneous intervention for suspected new onset of
CHD based on the clinical presentation, which was cate-
gorized as ECG abnormality (only positive stress ECG),
stable angina (stable exertional symptoms only), unstable
angina (progressive symptoms or symptoms at rest), or
MI (creatinine kinase [CK] level >636 IU/L and creatin-
ine kinase-myocardial band isoenzyme [CK-MB] index
>6%) in the catheter Lab at the Shanghai Ruijin Hospital
which is affiliated with the Shanghai Jiaotong University
School of Medicine . Written consent was obtained from
all individuals before they were enrolled in the study.
Their medical histories were obtained and recorded, and
pertinent baseline laboratory studies were drawn before
cardiac catheterization while BMI and GFR were calcu-
lated. All patients were treated with IV heparin and
combined antiplatelet therapy, while the use of IIb/IIIa
inhibitors was at the operator’s discretion. Telephone
interviews were performed at 6 months and participants
were readmitted for routine angiographic follow-up
1 year after the procedure, including those with normalangiography at their index visits. Necessary cardiac
catheterization was performed for recurrent symptoms
or objective evidence of ischemia. Individuals were
excluded from the study if they fell into one of the fol-
lowing criteria: Patients with histories of CHD or prior
coronary revascularization; patients undergoing CABG
instead of stenting; patients with heart failure or any
kind of cardiomyopathy; patients with familial hyper-
cholesterolemia; patients with severely impaired liver or
renal function; patients with a terminal illness with a life
expectancy of less than 1 year.
Laboratory studies and the assessment of insulin
resistance
After fasting for 12 hours, blood samples were drawn
from the patients at 8 AM, including both fasting glu-
cose and insulin concentration, HbA1c, hsCRP, liver
function tests, lipid panel, BUN, creatinine and urine
acid. In addition, OGTT and insulin concentrations were
also obtained 2 hours after oral ingestion of 75 mg glu-
cose by the central lab in the hospital without the know-
ledge of the study. Body mass index (BMI) was
calculated as weight divided by height squared (kg/m2).
We estimated insulin resistance by using the homeosta-
sis model assessment index of IR (HOMA-IR) developed
by Mathew [6], which was believed to have a close cor-
relation with euglycemic clamp for use in cross-sectional
studies [7]. We used the following formula HOMA-IR
= baseline insulin concentration (U/mL) × baseline glu-
cose concentration (mmol/L)/ 22.5 [6]. We obtained
HOMA-IR values from 284 individuals and subsequently
defined the cutoff value for insulin resistance as the
upper quartile of HOMA-IR obtained from all the sub-
jects involved in the study [8], which equals 3.458 in our
study. Also glomerular filtration rate (GFR) was calcu-
lated by adopting the Cockcroft-Gault equation (for
men: (140− age ×weight)/(72 × serum creatinine); for
women: (140− age ×weight) / (72 × serum creatinine ×
0.85)) [9].
Coronary angiography and Gensini score
Standard method was adopted and Judkins method was
deployed. All patients were admitted to the hospital the
day before CAG. The purpose of CAG was to diagnose
any ischemic conditions such as angina. After adminis-
tration of isosorbide dinitrate (2.5–5 mg bolus dose), the
coronary arteries were evaluated by 2 experienced cardi-
ologists. Narrowing of ≥50% in one of the three major
coronary arteries or their major branches was judged
significant while narrowing of <5% was considered in-
significant. We defined both residual narrowing of less
than 20% and third class TIMI blood flow as successful
outcomes of the procedure. The decision to deploy a
balloon or use a specific drug-eluting stent was made by
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ated in similar angiographic angles, and the percentage
of stenosis was determined with the use of calipers com-
paring the stenotic segment with the proximal, angiogra-
phically normal segment. Clodigrel, 75 mg per day, or
ticlopidine, 250 mg twice per day, was administered for
at least 12 months after the procedure and all patients
received 100 mg aspirin per day. The same guidelines
were implemented at 1-year follow-up for each subject.
We also adopted the modified Gensini scoring system to
evaluate both the baseline and the follow-up angiograms
[10]. To summarize this scoring system, five points were
given for left main lesion; 2.5 points for the proximal left
anterior descending artery (LAD) or left circumflex
(LCX); 1.5 points for mid-segment LAD; one point for
the distal segment of LAD, first diagonal branch, LCX
obtuse marginal branch or right coronary artery, and 0.5
points for the second diagonal branch or LCX postero-
lateral branch (Figure 1). To define the atherosclerotic
plaque progression, we divided the following patients
into the progression group: (1) patients who progressed
from normal or insignificant angiogram to CAD; (2)
Patients whose documented baseline lesions exacerbated
in the same vessel; (3) Patients who progressed from
their baseline CAD to new lesion(s) in a different vessel
in one-year period. In addition, we classified those who
had normal angiograms or similar CAD lesions at the
first and following visits into the non-progression group
[11].Definitions concerning conventional risk factors of CHD
Patients who had smoked in the past year were consid-
ered current smokers. The definition of hypertension
was a blood pressure that was equal to or higher thana b
Figure 1 Illustration of initial and follow-up visit angiograms obtaine
angiogram while Figure 1b is the follow-up angiogram from the same ang
arrows were presented to manifest different lesions. In addition, both lesion
permission from the catheter lab at the Shanghai Ruijin Hospital, affiliated140/90 mmHg after three measurements during the first
visit or those with previously established diagnosis of
hypertension or who were receiving antihypertensive
drugs. Individuals with at least two fasting plasma glu-
cose levels higher than 125 mg/dL or those being treated
for diabetes with oral hypoglycemic agents and/or insu-
lin were considered diabetic. Patients were considered
dyslipidemic if the individual had cholesterol levels
higher than 200 mg/dL or triglyceride levels higher than
150 mg/dL or if they were receiving lipid-lowering
drugs.Statistical analysis
We adopted SPSS11.0 for all the statistical analyses
related to the study. Measurement data were expressed
as mean and SD while count data were presented as per-
centage (%). We used the paired t-tests for continuous
variables and the χ2 test or the Fisher exact for categor-
ical variables. Nonparametric methods were preferred to
handle non-normally distributed data. Several conven-
tional and novel risk factors such as age, body mass
index (BMI), hypertension, DM, LDL-C, HbA1c, hs-CRP
, urine MA/Cr and HOMA-IR were included in the
multivariate logistic regression model to determine their
independent effects on the progression of atherosclerotic
plaques. Differences were considered statistically signifi-
cant when the p value was less than 0.05.Results
Baseline demographics and lab results in the progression
group versus non-progression group
A total of 377 patients were consecutively included dur-
ing the 4-year period and 366 participants received their
follow-up angiography, with 198 individuals included ind from one single participant. Figure 1a depicts the index
le. To visualize the coronary lesions progression, two sets of colored
s progressed during the 1 year follow-up. Figures were obtained with
to Shanghai Jiaotong University School of Medicine.
Table 2 Comparison of laboratory results between the












Fasting glucose (mmol/L) 6.15 ± 1.81 5.49 ± 1.25 <0.001
7.84 ± 1.80 5.30 ± 1.22 0.005
OGTT (mmol/L) 10.09 ± 4.17 8.65 ± 3.41 <0.001
9.68 ± 3.79 8.47 ± 3.38 0.002
Fasting insulin (mU/L) 13.50 ± 26.58 12.57 ± 27.04 0.010
14.43 ± 19.01 17.10 ± 60.81 0.002
Postprandial insulin
(mU/L)
78.31 ± 117.74 62.43 ± 65.86 0.388
80.27 ± 71.31 88.35 ± 107.35 0.868
Bennett index 1.79 ± 0.65 0.41 ± 0.56 <0.001
0.95 ± 0.84 0.67 ± 0.95 <0.001
HbA1c (%) 6.73 ± 1.40 6.24 ± 0.98 0.001
6.79 ± 1.53 6.07 ± 0.78 <0.001
hsCRP (mg/L) 9.28 ± 13.56 13.34 ± 22.51 0.600
6.55 ± 12.01 2.68 ± 4.14 0.048
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lesions in different vessels and 134 patients with pro-
gression in the same vessel) and 168 in the non-
progression group. Table 1 lists baseline demographic
data for both groups. No significant difference can be
seen between the two groups except for DM prevalence
(42.9% versus 30.4%, p= 0.013), NGR prevalence (33.8%
versus 51.2%, p= 0.001) and oral glucose lowering agent
(35.9% versus 21.6%, p= 0.002). In addition, both initial
clinical presentations and medications patients received
at discharge were similar in the two groups.
Table 2 compares the lab results between the two
groups, revealing that the progression group had a
worse performance than the non-progression group in
the glucose panel including fasting glucose (6.15 ± 1.81
versus 5.49 ± 1.25, p <0.001 and 7.84 ± 1.80 versus
5.30 ± 1.22, p< 0.005), OGTT (10.09 ± 4.17 versus
8.65 ± 3.41, p< 0.001 and 9.68 ± 3.79 versus 8.47 ± 3.38,
p= 0.002) and HbA1c (6.73 ± 1.40 versus 6.24 ± 0.98,
p= 0.001 and 6.79 ± 1.53 versus 6.07 ± 0.78, p< 0.001).
Moreover, although significant differences in fasting in-
sulin could be observed, the result for each subjectTable 1 Baseline demographic data of the progression





Group (n = 168)
p value
Age 65.83 ± 11.46 64.74 ± 10.19 0.375
Sex(Man/Women) 158/40 139/29 0.474
BMI (kg/m2) 25.47 ± 3.18 24.80 ± 3.63 0.421
Hypertension (%) 153 (77.3) 121 (72.5) 0.289
Diabetes (%) 85 (42.9) 51 (30.4) 0.013
NGR (%) 67 (33.8) 86 (51.2) 0.001
IFG (%) 13 (6.6) 7 (4.2) 0.362
IGT (%) 20 (10.1) 18 (10.8) 0.865
IFG + IGT (%) 13 (6.6) 6 (3.6) 0.241
Initial admission n (%)
ECG abnormalities 24 (12.1) 12 (7.1) 0.111
Stable Angina 29 (14.6) 33 (19.6) 0.204
Unstable Angina 86 (43.4) 70 (41.7) 0.733
Non-ST elevated AMI 10(5.1) 9(5.4) 0.895
ST elevated AMI 49 (24.7) 44 (26.2) 0.752
Medication (%)
Statin 196 (99.5) 165 (98.8) 0.468
CCB 67(29.6) 55(32.9) 0.806
ACEI/ARB 104 (53.6) 76 (46.1) 0.154
β-blocker 164 (82.8) 128(76.6) 0.141
Oral glucose lowering dug 70(35.9) 35(21.2) 0.002
Application of insulin 9(4.5) 11(6.5) 0.491
BUN (mmol/L) 5.44 ± 1.59 5.45 ± 1.50 0.941
6.06 ± 1.90 5.70 ± 1.48 0.623
Creatinine (umol/L) 84.47 ± 18.34 89.90 ± 36.51 0.671
93.11 ± 23.46 87.28 ± 18.87 0.585
Urine acid (umol/L) 339.83 ± 76.41 339.30± 85.77 0.878
358.38 ± 81.25 362.80± 79.00 0.966
Urine Ma/Cr 12.12 ± 49.70 3.65 ± 18.74 0.011
16.00 ± 69.94 2.09 ± 3.14 0.366
GFR (ml/min) 80.16 ± 25.46 76.62 ± 28.98 0.345
73.52 ± 25.48 71.55 ± 23.33 0.049
Serum triglyceride
(mmol/L)
2.13 ± 1.72 1.86 ± 2.01 0.072
1.76 ± 1.34 1.65 ± 1.50 0.207
Serum cholesterol
(mmol/L)
4.58 ± 1.22 4.18 ± 1.09 0.103
2.08 ± 0.76 2.05 ± 0.78 0.412
HDL (mmol/L) 1.05 ± 0.23 1.05 ± 0.26 0.706
1.06 ± 0.26 1.14 ± 0.26 0.246
LDL (mmol/L) 2.81 ± 0.96 2.45 ± 0.84 0.118
2.08 ± 0.76 2.05 ± 0.78 0.412
Lpa (mmol/L) 0.21 ± 0.21 0.20 ± 0.18 0.941
0.21 ± 0.17 0.30 ± 0.49 0.317
ApoA (mmol/L) 1.13 ± 0.22 1.12 ± 0.20 0.764
1.11 ± 0.22 1.12 ± 0.29 0.738
ApoB (mmol/L) 0.93 ± 0.28 0.87 ± 0.26 0.342
0.80 ± 0.25 0.77 ± 0.23 0.225
Ejection Fraction 62.50 ± 9.06 64.01 ± 6.86 0.331
62.62 ± 8.38 62.62 ± 8.20 0.153
Table 4 Comparison of changes in lab results between
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(13.50 ± 26.58 versus 12.57 ± 27.04, p= 0.010 and
14.43 ± 19.01 versus 17.10 ± 60.81, p= 0.002). The Bon-
net index, the log-transform of HOMA-IR, was mark-
edly elevated in the progression group compared with
non-progression group (1.79 ± 0.65 versus 0.41 ± 0.56, p
< 0.001 and 0.95 ± 0.84 versus 0.67 ± 0.95, p< 0.001).
The lipid panel between two groups was similar while
both the urine mAlb/Cr at index visit (12.12 ± 49.70
versus 3.65 ± 18.74, p= 0.011) and GFR (73.52 ± 25.48
versus 71.55 ± 23.33, p= 0.049) at the follow-up visit
were significantly higher in the progression group.
Table 3 shows index clinical presentations and angiog-
raphy characteristics. No significant difference could be
observed between the two groups.
We also obtained the changes in lab results by calcu-
lating the difference value between index and follow-up
visits. Table 4 depicts the changes in lab results and their
relationship with progression of atherosclerosis. During
the course of the study, the glucose panel was elevated
in the progression group compared with the non-
progression group, including OGTT, which was signifi-










STEMI 49 (24.7) 44 (26.2) 0.752
NSTEMI 10 (5.1) 9 (5.4) 0.895
SAP 29 (14.6) 33 (19.6) 0.204
UAP 86 (43.4) 70 (41.7) 0.733
ECG abnormalities 24 (12.1) 12 (7.1) 0.111
Number of vessel affected n 0.332
(%)
Without lesions 2 (1.0) 4 (2.4)
Single vessel 50 (25.3) 56 (33.3)
Double vessel 69 (34.8) 55 (32.7)
Three vessel 74 (37.4) 51 (30.4)
Multiple vessel 3 (1.5) 2 (1.2)
Characteristics of lesion n
(%)
Diffuse lesion 51 (25.8) 53 (31.5) 0.221
Calcification 14 (7.1) 21 (12.5) 0.078
Bifurcation 13 (6.6) 16 (9.5) 0.296
Opening lesion 14 (7.1) 16 (9.5) 0.394
Occlusive lesion 37 (18.7) 33 (19.6) 0.817Follow-up lab results, angiogram and Gensini score
between the Higher Insulin Resistant group and Lower
Insulin Resistant group
To investigate the IR further, we divided all partici-
pants into the higher IR group (71) and the lower IR
group (213) based on the HOMA-IR cutoff value,
which was 3.458 in our study. Table 5 presents the
lab results from follow-up visits between two groups.
Subjects in the higher IR group had markedly elevated
laboratory values compared to the lower IR group, in-
cluding BMI (27.69 ± 4.17 versus 24.13 ± 2.65, p
< 0.001), prevalence of hypertension (84.5% versus
70.0%, p= 0.013), prevalence of diabetes (62.0% versus
33.8%, p< 0.001), fasting glucose (39.36 ± 9.93 versus
8.73 ± 3.43, p= 0.005), OGTT (10.51 ± 3.98 versus
8.73 ± 3.43, p= 0.002), fasting insulin (39.36 ± 96.93 ver-
sus 10.36 ± 9.56, p= 0.002), postprandial insulin
(135.52 ± 148.57 versus 68.41 ± 60.23, p< 0.001), bon-
net index (0.95 ± 0.84 versus 0.67 ± 0.95, p< 0.001) and
HbA1c (6.79 ± 1.53 versus 6.07 ± 0.78, p< 0.001 ). In








Glucose 0.21 ± 2.20 −0.19 ± 1.27 0.136
OGTT −0.42 ± 3.92 −0.67 ± 2.87 0.025
Insulin 6.00 ± 23.46 2.42 ± 11.90 0.347
Insulin2h 20.75 ± 58.80 14.65 ± 49.81 0.200
SBP −6.80 ± 21.76 2.68 ± 19.54 0.327
DBP −5.65 ± 11.95 −1.58 ± 13.80 0.637
PP −1.15 ± 18.76 4.26 ± 15.99 0.925
MAP −6.03 ± 13.22 −0.16 ± 14.05 0.517
HbA1c 0.17 ± 1.28 0.02 ± 0.97 0.339
hsCRP −4.61 ± 18.68 −11.19 ± 21.90 0.659
BUN 0.22 ± 1.39 0.48 ± 1.85 0.525
Creatinine 3.33 ± 16.63 4.28 ± 10.42 0.948
UA 20.25 ± 49.91 41.06 ± 70.41 0.311
GFR −3.17 ± 12.38 −5.90 ± 14.05 0.520
Urine Malb/Cr 0.89 ± 66.12 0.20 ± 1.83 0.491
TG −0.29 ± 0.91 −0.36 ± 1.58 0.279
TC −0.90 ± 0.91 −0.57 ± 1.09 0.285
LDL 0.16 ± 0.43 0.16 ± 0.30 0.321
HDL 0.02 ± 0.22 0.06 ± 0.21 0.124
Lpa −0.01 ± 0.09 0.14 ± 0.59 0.114
ApoA 0.02 ± 0.23 0.11 ± 0.25 0.919
ApoB −0.09 ± 0.26 −0.08 ± 0.23 0.609
LVEF −1.05 ± 5.65 −0.43 ± 5.83 0.561
We calculate the changes in laboratory results by deducting the index value
from the follow-up value.
Table 5 Comparison of lab results between the higher IR
and lower IR groups (only variables considered








BMI 27.69 ± 4.17 24.13 ± 2.65 <0.001
Prevalence of hypertension 60 (84.5%) 148 (70.0%) 0.013
Prevalence of diabetes 44 (62.0%) 72 (33.8%) <0.001
Fasting glucose 7.84 ± 1.80 5.30 ± 1.22 0.005
OGTT 10.51 ± 3.98 8.73 ± 3.43 0.002
Fasting insulin 39.36 ± 96.93 10.36 ± 9.56 0.002
Postrandial insulin 135.52 ± 148.57 68.41 ± 60.23 <0.001
Bonnet index 0.95 ± 0.84 0.67 ± 0.95 <0.001
HbA1c 6.79 ± 1.53 6.07 ± 0.78 <0.001
GFR 79.46 ± 28.19 70.38 ± 21.72 0.016
Triglycerides 2.09 ± 1.75 1.52 ± 1.01 0.002
hsCRP 8.54 ± 13.78 3.87 ± 7.45 0.005
We divided the subjects into higher IR group and lower IR group based on the
cutoff value, defined as the highest quartile of HOMA-IR from 366 participants
and equaled to 3.458 in our study.
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(2.09 ± 1.75 versus 1.52 ± 1.01, p= 0.002) and hsCRP
(8.54 ± 13.78 versus 3.87 ± 7.45, p= 0.005) were signifi-
cantly elevated in the higher IR group compared to the
lower IR group. Characteristics of follow-up angiograms
demonstrated that the higher IR group had a markedly
increased rate of plaque progression (65.7% versus 47.6,
p= 0.009), new lesion in different vessels (47.1% versus
27.4%, p= 0.002) and exacerbation of original lesion
(22.9% versus 9.0%, p= 0.002) than in the lower IR group
(Table 6). Moreover, while the initial and follow-upTable 6 Comparison of the Gensini score and the pattern
of follow-up angiograms between the higher IR and
lower IR groups
Higher IR




Initial gensini score 9.09 ± 14.33 9.44 ± 12.88 0.813
Follow-up gensini score 17.21 ± 18.46 14.09 ± 14.18 0.358
Difference value during 8.13 ± 11.83 4.65 ± 7.58 0.019
1-year peroid
Follow-up angiogram (%)
Progression of plaques 46(65.7) 101(47.6) 0.009
Revascularization 28 (40.6) 77(36.7) 0.561
New lesion in different 33 (47.1) 58 (27.4) 0.002
vessel
Exacerbation of original 16 (22.9) 19 (9.0) 0.002
lesion
In-stent restenosis 13(18.3) 31(14.6) 0.449Gensini scores were similar between these two groups
(9.09± 14.33 versus 9.44± 12.88, p=0.813 and
17.21 ± 18.46 versus 14.09 ± 14.18, p =0.358), the differ-
ence value during the follow-up is markedly elevated in
the higher IR group than the lower IR group (8.13 ± 11.83
versus 4.65± 7.58, p= 0.019) (Figures 2 and 3).
Multivariable regression analysis of related risk factors
towards atherosclerotic progression
We assessed the impact of conventional and novel risk
factors on the coronary atherosclerosis progression by
using a multivariate logistic regression analysis (Table 7).
Risk factors including age, sex, BMI, prevalence of
hypertension or diabetes, HOMA-IR> 3.458, HbA1c,
hsCRP, LDL-C, urine MA/Cr and change in OGTT were
entered in the model and the results revealed that both
HOMA-IR> 3.458(OR = 4.969, p= 0.010) and HbA1c
(OR= 1.721, p= 0.034) were independent predictors of
progression of coronary lesions.
We then divided all subjects into the diabetic (n = 136)
and non-diabetic groups (n = 230) to investigate the role
of insulin resistance in the development of atheroscler-
otic plaques separately. The same binomial regression
models were set up except the input of prevalence of
diabetes mellitus (Table 8). Insulin resistance remained
an independent predictor for progression of coronary
lesions in both groups according to the result. In
addition, because HOMA-IR could be modeled as a lin-
ear continuous variable or a categorical variable divided
by its cutoff value [12,13], we subsequently tested
HOMA-IR from both perspectives. The result revealed
that HOMA-IR was an independent predictor of athero-
sclerotic progression, which was consistent with our
early findings.
Discussion
Our study explored the effect of insulin resistance on the
progression of atherosclerotic plaques over a 1-year
follow-up interval. The difference value of Gensini score
between the higher IR group and the lower IR group was
statistically significant and the binomial multivariate re-
gression models contended that insulin resistance was an
independent predictor of atherosclerotic progression in
patients with coronary heart disease irrespective of the
individual’s diabetes status. Insulin resistance generally
occurs in cluster with other risk factors including hyper-
glycemia, dyslipidemia and inflammatory conditions. IR
itself is a phenomenon that decreases the effects pro-
duced by the normal activity of insulin [13]. In addition,
one of its key biochemical defects lies in the specific im-
pairment of PI3K-dependent signaling pathways while
other pathways including MAPK were intact [14], which
results in the overproduction of ET-1 over eNOS, leading

















Figure 2 Comparison of Gensini scores between the higher IR group and lower IR group at the initial/follow-up visits. p <0.05 was
considered statistically significant. Different colors represent different variables as listed on the right. Both index and follow-up Gensini score
remained similar between the higher and lower IR groups (9.09 ± 14.33 versus 9.44 ± 12.88, p= 0.813 and 17.21 ± 18.46 versus 14.09 ± 14.18, p
=0.358) while the difference value was significantly elevated in the higher than the lower IR group.
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mation of atherosclerotic plaques [15]. Early studies have
already supported the idea that IR is an important pre-
dictor of CHD [16]. Tetsuya conducted a prospective
study and found that IR is associated with coronary lipid-
rich plaques in patients with abnormal glucose regulation
[17]. Reports have also indicated that IL-6, a potential
cardiometabolic biomarker expressing in humanFigure 3 Error bars demonstrating differences in index and follow-up
bar represents a variable as listed on the X axis. The Y axis demonstrates th
mean value and standard deviation. The red circle indicates that difference
4.65 ± 7.58, p= 0.019).atherosclerotic lesions, has a close relationship with
HOMA-IR [18]. Uli C argues that low adiponectin levels
are frequently associated with insulin resistance, may
have a closer link with coronary plaque vulnerability,
which plays an important role in the pathogenesis of
ACS [19]. Having enrolled 543 patients with diabetes and
CHD and using the intravascular ultrasound (IVUS)
technique to assess the progression of coronaryGensini score between the Higher and Lower IR group. Each error
e 95% confidence interval of each different Gensini score, including its
value of Gensini score was statistically significant (8.13 ± 11.83 versus
Table 7 Regression analysis of risk factors for plaque
progression concerning all participants
Variable OR value 95%CI p value
HOMA-IRI> 3.458 4.969 0.630-6.475 0.011
HbA1c 1.721 0.256-4.515 0.034
Abbreviations: CI, confidence interval; HbA1c, glycosylated hemoglobin;
HOMA-IRI, homeostasis model assessment insulin resistance index; hsCRP, high
sensitive C - reactive protein; OR, odds ratio.
Binomial regression analysis was performed across the entire study group.
Regression model included both conventional and novel risk factors for
coronary plaque progression such as age, sex, body mass index, hypertension,
diabetes mellitus, follow-up urine microalbumin/creatinine, follow-up hsCRP,
follow-up HbA1c, follow-up LDL. Change in OGTT was also included.
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concluded that pioglitazone, a drug targeting IR, could
significantly slow the progression of atherosclerosis,
which is also supportive of our study [20].
Having confirmed the predictive value of IR on pla-
ques progression, our study also looks into the issue of
in-stent restenosis, an important complication of coron-
ary arterial intervention nowadays [21]. Having observed
similar prevalence of in-stent restenosis between the
higher and lower IR groups, we set up the binary logistic
regression model to evaluate the risk factors for in-stent
restenosis by inputting the same variables as above. The
results showed that unlike prevalence of HTN (OR=
0.241, p= 0.019) and age (OR= 1.084, p= 0.008), insulin
resistance had no statistically significant effect on the de-
velopment of in-stent restenosis (OR= 2.064, p= 0.218,
table not shown). It has been well studied that the for-
mation of in-stent restenosis depends on the prolifera-
tion of in-stent neointimal cells because of complex
inflammatory responses in the short time interval, which
is quite different from the process of plaque formation
[21,22]. This may serve to explain the results of our
study. However, conflicting evidence does exist. A study
in 2005 by Kazuaki stated that IR predicted in-stent re-
stenosis rather than de-novo stenosis, which was
mediated by atherosclerosis plaque progression [7]. Fol-
lowing the difference can be utilized to explain the dif-
ferences in results between their study and ours
according to the following facts: 1. the aim of the studyTable 8 Logistic Regression of Risk Factors in both
Diabetic Participants and non-Diabetic Participants
Subgroups Variable OR value 95%CI p value
Non-DM HOMA-IRI> 3.458 7.528 0.973-4.300 0.034
DM HOMA-IRI> 3.458 7.590 0.987-4.220 0.040
Abbreviations: CI, confidence interval; DM, diabetes mellitus; HbA1c,
glycosylated hemoglobin; HOMA-IRI, homeostasis model assessment insulin
resistance index; hsCRP, high sensitive c-reactive protein; OR, odds ratio.
Binomial regression was performed separately in the non-DM (n= 230) and
DM groups (n = 136). The model included both conventional and novel risk
factors for coronary plaque progression such as age, sex, body mass index,
hypertension, follow-up urine microalbumin/creatinine, follow-up hsCRP,
follow-up HbA1c, follow-up LDL.by Kazuaki was to evaluate the IR’s effect on restenosis
after stenting, which resulted in the 110 recruited indivi-
duals were not just confined to subjects with CHD. In-
stead, the sample included patients who had extensive
coronary artery dissection after PTCA, complete vessel
closure, residual stenosis of 25% or more of the vessel
diameter. 2. The follow-up interval in Kazuaki’s study,
which played an important role in the development of
in-stent restenosis was 4-months. In our case, the inter-
val was 1 year. 3. Instead of setting up a cutting value
for HOMA-IR to determine the state of insulin resist-
ance as we did, they set the HOMA-IR as a continuous
variable. 4. The variables they used in the multivariable
logistic regression model only included HbA1C,
HOMA-IR and LDL-C, which in our case are risk fac-
tors such as age, sex, BMI, prevalence of hypertension
and diabetes, HOMA-IR, HbA1c, hsCRP, LDL-C and
urine MA/Cr. Based on these differences in the funda-
mental aspects of the studies, it seems inappropriate to
compare their results with ours.
Our study also revealed that HbA1c also stands for an
independent predictor of coronary plaque progression in
unselected individuals. As a reliable marker of recent 2–
3 months serum glucose level, HbA1c has already been
used for diagnosing diabetes mellitus [23,24]. In a recent
meta-analysis covering 20 studies involving 13, 224 indi-
viduals suggested that HbA1c level was an independent
risk factor for mortality in CHD patients without dia-
betes [25]. Hiroyasu also stated that HbA1c was an inde-
pendent predictor of major adverse cardiac events after
the implantation of DES [26]. Several other studies also
support the role of HbA1c in future CVD event and
mortalities [27–29].
Study limitations
First, the number of subjects recruited in the study was
limited and all individuals were enrolled from a single
center at the Shanghai Ruijin hospital. In addition, the ma-
jority of patients originated from Shanghai, Jiangsu prov-
ince and Zhejiang province, all confined to the southeast
region of the Yangzi River in Mainland China. Moreover,
due to the limited number of individuals in subgroups
such as the IGT group (n= 57) and the IFG group (n= 39),
our study did not perform the subgroup analysis and fu-
ture studies may provide different results, as the patho-
genesis of IGT is different from that of IFG concerning
insulin resistance [30]. Finally, discordant views did exist
in assessing insulin resistance by using the HOMA-IR
method, including the lack of consensus on setting up a
unified cutoff value for HOMA-IR to determine the state
of IR [31]. We chose to set the upper quartile of HOMA-
IR in the background population as its cutoff value [8,10],
which equaled 3.458 in our study. However, we also mod-
eled HOMA-IR as a linear continuous variable and tested
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results conformed to each other.
Conclusions
Insulin resistance is an independent predictor for athero-
sclerosis plaque progression in patients with coronary heart
disease in both the diabetic and non-diabetic population.
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